Painchek Ltd · ASX:PCK
Painchek — Investor Presentation (January 2023)
26 slides from Painchek's investor presentation, Jan 31, 2023
Slide 1: Investor Webinar Presentation
ASX ANNOUNCEMENT 31st January 2023 INVESTOR WEBINAR PRESENTATION For personal use only TUESDAY, 31 JANUARY 2023 Further to the webinar announcement on 25th January, PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitorin
Slide 2: PainChek Shared Care Program
The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review. To find out more, visit
Slide 3: Company Presentation January 2023
For personal use only Company Presentation January 2023 Philip Daffas - CEO & Managing Director PAI N C H EK LTD | ASX:PC K 1 |
Slide 4: Our purpose is to give a voice to people who cannot reliably verbalise their pain
Our purpose is to give a voice to people who cannot reliably verbalise their pain For personal use only 2 |
Slide 5: The Breadth of the PainChek Global Market Opportunity
THE BREADTH OF THE PAINCHEK GLOBAL MARKET OPPORTUNITY For personal use only 400Mpre-verbal children 25-42% of hospital beds occupied by people with dementia 57M people living with dementia >150M expected by 2050 1. Ecology Communications Group. www.ecology.com/birth-death-rates 2. World Alzheimer Re
Slide 6: The PainChek Universal App: Quick and Easy Operation
THE PAINCHEK® UNIVERSAL APP: QUICK AND EASY OPERATION For personal use only Automated facial pain analysis: A medical • 3 second video of patient face device in • recognises 9 micro-facial your pocket expressions indicative of pain Digital questionnaire checklist: • guides the carer in other pain as
Slide 7: Existing Aged Care Customer Contracts
EXISTING AGED CARE CUSTOMER CONTRACTS For personal use only CUSTOMER FEE PAYING LICENCES LICENCES / ARR $M $2.1 45,000 $2.0 $0.6M $4.4M 40,000 $1.8 $1.1M 35,000 $1.6 $1.5 30,000 $1.3 $0.3M 25,000 $0.3M $1.0 45,259 $1.0 20,000 $2.1M 36,555 31,977 15,000 26,501 $0.5 10,000 20,806 5,000 - $- DEC-21 MAR
Slide 8: PainChek's Existing EMR & Medication Management and Integration Partners
PAINCHEK’S EXISTING EMR & MEDICATION MANAGEMENT AND INTEGRATION PARTNERS For personal use only PainChek integrates and works with aged care management and medication management systems covering more than 180,000 aged care beds in Australia, 25,000 beds in New Zealand, 195,000 beds in the UK & Irelan
Slide 9: Independent Impact Evaluation - KPMG
For personal use only INDEPENDENT IMPACT EVALUATION - KPMG 7 |
Slide 10: Australian Federal Government Funded PainChek National Roll-out
AUSTRALIAN FEDERAL GOVERNMENT FUNDEDPAINCHEK® NATIONAL ROLL -OUT For personal use only AT THE TIME OF THE EVALUATION Between December 2019 and June 2022 of residential Aged Care PainChek® was rolled-out across the Australian Residential Aged Care industry in 51% Providers across Australia participat
Slide 11: Australian Federal Government Funded PainChek National Roll-out: Outcomes
AUSTRALIAN FEDERAL GOVERNMENT FUNDED PAINCHEK® NATIONAL ROLL-OUT For personal use only KMPG’s evaluation identified a wide array of both quantitative and qualitative positive outcomes following adoption of PainChek® by the studied cohort. FACILITIES 85% 85% of survey respondents reported benefits of
Slide 12: Australian Federal Government Funded PainChek National Roll-out: Case Studies
AUSTRALIAN FEDERAL GOVERNMENT FUNDED PAINCHEK® NATIONAL ROLL-OUT For personal use only A number of case studies were carried out by the KPMG team, highlighting cases where the rollout had demonstrated benefits for individuals receiving care. The below summaries capture 3 such examples. PainChek® ide
Slide 13: PainChek Global Market Strategy
PAINCHEK GLOBAL MARKET STRATEGY For personal use only BUSINESS MODEL TARGET MARKETS/USERS B2B Enterprise: licence • Dementia &/geriatric wards • Hospitals • ER/Post surgical care • Care Homes • Residential & home care providers • Home care Healthcare • Primary Care PainChek Professionals Adult BUSIN
Slide 14: UK - Increasing Penetration into the 440,000 Bed Residential Aged Care Market
UK –INCREASING PENETRATION INTO THE 440,000 BED RESIDENTIAL AGED CARE MARKET For personal use only “The greatest achievement to date is a marked decrease in antipsychotic use in those UK market traction living with dementia. ” Government funded Cheryl Baird, Director of growing –10,000 New RAC clien
Slide 15: PainChek Case Study: Orchard Care Homes
For personal use only PAINCHEK® CASE STUDY ORCHARD CARE HOMES 13 |
Slide 16: Empowering Pain Management with AI at Orchard Care Homes
EMPOWERING PAIN MANAGEMENT WITH AI AT ORCHARD CARE HOMES For personal use only Since implementing PainChek®, Orchard Care Homes has achieved: • 100% increase in frequency of pain assessments • 50% increase in number of residents on regular pain relief as a result of newly identified pain • 50% reduc
Slide 17: PainChek Helping to Improve Pain Management Outcomes in U.K. Aged Care Homes
PAINCHEK HELPING TO IMPROVE PAIN MANAGEMENT OUTCOMES IN U.K. AGED CARE HOMES For personal use only Pain management Medication & QoL improvements improvements • 100% increase in frequency • 33% reduction of of pain assessments antipsychotic drug use (46% stopped use) • 50% increase in number of resid
Slide 18: Market Partnership Agreement for USA & Canada Aged Care
MARKET PARTNERSHIP AGREEMENT FOR USA & CANADA AGED CARE For personal use only PointClickCare is the leading care management software system provider to nursing homes in USA & Canada - 1,000,000+ beds PainChek to be integrated Pilots in Canada Q4 CY22, into PointClickCare platform USA to commence upo
Slide 19: PainChek's Global Users and Market Access
PAINCHEK’S GLOBAL USERS AND MARKET ACCESS For personal use only Canada • Initial RAC sales Europe (EU) now in place • Targeting RAC beds and • Exploring Home care dementia additional Aged patients in EU Care and Home • Exploring International Japan Care partners for partnerships with large • Patent
Slide 20: Consequences of Poorly Managed Pain for Hospitalised Dementia Patients
CONSEQUENCES OF POORLY MANAGED PAIN FOR HOSPITALISED DEMENTIA PATIENTS For personal use only Longer Increased High use of hospital stay delirium risk Antipsychotics 18 3.26 54% days times 1. Germossa et al. BMC Nursing (2019) 18:40 https://doi.org/10.1186/s12912-019-0362-y 2. Tsai, I. P., Jeong, S.
Slide 21: InterSystems Partnership for Hospital Market
CONSEQUENCES OF POORLY MANAGED PAIN FOR HOSPITALISED DEMENTIA PATIENTS For personal use only InterSystems – global EMR provider managing more than 1 billion health records PainChek mobile App to be integrated with InterSystems IRIS interoperability platform and TrakCare EMR Integration addresses hos
Slide 22: InterSystems TrakCare EMR Around the World
INTERSYSTEMS TRAKCARE EMR AROUND THE WORLD For personal use only 500+ TrakCare sites around the globe CAMBRIDGE, USA World Headquarters Deployed in 27 countries Serving a patient SYDNEY, AU population of 100 APAC Regional Headquarters million+ 20 |
Slide 23: PainChek in Hospital - The Fifth Vital Sign
PAINCHEK IN HOSPITAL – THE FIFTH VITAL SIGN PainChek and InterSystems have developed a hospital version of PainChek incorporating clinical workflows and For personal use only full integration within the TrakCare EMR - providing nurses and doctors with the following capability: Early warning alerts f
Slide 24: Corporate Summary
CORPORATE SUMMARY For personal use only Financial information Share price (27 January 2023) A$0.029 Shares on issue 1,296.4m Market capitalisation A$37.6m Cash (31 December 2022) A$4.8m Unlisted options/performance rights 40.6m Debt Nil Top shareholders % Peters Investments Proprietary Ltd 9.14% Boa
Slide 25: PainChek Company Highlights
PAINCHEK COMPANY HIGHLIGHTS For personal use only PATENT PROTECTED OFFERING PROVEN & DOMINANT MARKET IMPROVING OUTCOMES FOR POSITION IN AU PATIENTS RAPIDLY GROWING ARR WITH UNTAPPED POTENTIAL IN STRONG RETENTION RATE INFANTS/CHILDREN’S MARKET INTERNATIONAL EXPANSION MULTIPLE LARGE GLOBAL MARKET UNDE
Slide 26: Contact
The universal pain assessment solution for all residents in all situations For personal use only C O N T ACT P hi l ip D a ffa s, C E O & MD PAINCHEK LTD p hi l i p .daffa s@p a inche k.co m ASX:PCK 24 |